Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)

Amyloid

Volumn 22, Issue 3, 2015, Pages 175-180

  Cho, Younhee ^a   Baranczak, Aleksandra ^a   Helmke, Stephen ^b   Teruya, Sergio ^b   Horn, Evelyn M ^c   Maurer, Mathew S ^b   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Senile systemic amyloidosis; Vyndaqel; wild type TTR amyloid cardiomyopathy

Indexed keywords

PREALBUMIN; TAFAMIDIS; TETRAMER; BENZOXAZOLE DERIVATIVE; NEUROPROTECTIVE AGENT; RECOMBINANT PROTEIN;

AGED; ARTICLE; CARDIAC PATIENT; CASE REPORT; CHRONOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DISSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; HEART AMYLOIDOSIS; HUMAN; MALE; OPTIMAL DRUG DOSE; PERSONALIZED MEDICINE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSTHYRETIN AMYLOIDOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; AMYLOID NEUROPATHIES, FAMILIAL; BLOOD; CARDIOMYOPATHIES; CHEMISTRY; COMPLICATION; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; KINETICS; METABOLISM; PATHOLOGY; PROTEIN STABILITY;

AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; CARDIOMYOPATHIES; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; KINETICS; MALE; NEUROPROTECTIVE AGENTS; PREALBUMIN; PRECISION MEDICINE; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 84940035415     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2015.1063485     Document Type: Article

References (33)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New Engl J Med 2003;349:583-96.
2. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333-66.
3. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101-6.
4. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medial center. Aging Health 2013;9: 229-35.
5. Coelho T, Maia LF, Martins da Silva A, Cruz MW, Plante-Bordeneuve V, Lozeron P, Campistol JM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial. Neurology 2012;79:785-92.
6. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-16.
7. Coelho T, Maia LF, Martins da Silva A, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceiçao I, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260:2802-14.
8. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. JAMA 2013;310: 2658-67.
9. Andrade CA. Peculiar form of peripheral neuropathy-familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-27.
10. Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol 1996;9:355-9.
11. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629-34.
12. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agencyapproved drug. J Mol Biol 2012;421:185-203.
13. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843-5.
14. Mohammed SF, Mirzoyez SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113-22.
15. Benson MD. Familial amyloidotic polyneuropathy. Trends Neurosci 1989;12:88-92.
16. Falk RH. Cardiac amyloidosis a treatable disease, often overlooked. Circulation 2011;124:1079-85.
17. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. New Engl J Med 1997;336:466-73.
18. Monaco HL, Rizzi M, Coda A. Structure of a complex of 2 plasmaproteins-transthyretin and retinol-binding protein. Science 1995; 268:1039-41.
19. Schreiber G, Richardson SJ. The evolution of gene expression, structure and function of transthyretin. Comp Biochem Phys B 1997;116:137-60.
20. Blake CCF, Geisow MJ, Oatley SJ, Rerat B, Rerat C. Structure of pre-albumin-secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8-A. J Mol Biol 1978;121: 339-56.
21. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-60.
22. Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004;43:7365-81.
23. Babbes ARH, Powers ET, Kelly JW. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 2008; 47:6969-84.
24. Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc 2005;127:5540-51.
25. Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8:519-26.
26. Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, Helmke S, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry 2014;53:1993-2006.
27. Wiseman RL, Green NS, Kelly JW. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry 2005;44:9265-74.
28. Oppenhei JH, Surks MI, Bernstein G, Smith JC. Metabolism of iodine-131-labeled thyroxine-binding prealbumin in man. Science 1965;149:748-50.
29. Socolow EL, Woeber KA, Purdy RH, Holloway MT, Ingbar SH. Preparation of I131-labeled human serum prealbumin and its metabolism in normal and sick patients. J Clin Invest 1965;44: 1600-9.
30. Schneider F, Hammarstrom P, Kelly JW. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 2001;10:1606-13.
31. Keetch CA, Bromley EHC, McCammon MG, Wang N, Christodoulou J, Robinson CV. L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J Biol Chem 2005;280:41667-74.
32. Genereux JC, Qu S, Zhou M, Ryno LM, Wang S, Shoulders MD, Kaufman RJ, et al. Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis. EMBO J 2015;34:4-19.
33. Shoulders MD, Ryno LM, Genereux JC, Moresco JJ, Tu PG, Wu C, Yates III JR, et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep 2013;3:1279-92.